Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)

This Phase I study evaluated the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine (PCV), via subcutaneous (SC) or intramuscular (IM) administration, in healthy Japanese infants 3 months of age. A total of 133 participants were randomized to receive four do...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Yasunori Ishihara, Haruo Kuroki, Hidenobu Hidaka, Kazuyuki Iwai, Keiko Wan, Masayoshi Shirakawa, Miyuki Sawata
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-01-01
Subjects:	clinical trial pcv15 pcv13 dtap–ipv pneumococcal infections pneumococcal vaccines japan child infant
Online Access:	http://dx.doi.org/10.1080/21645515.2023.2180973